Charles River Laboratories International (CRL) Revenue (2009 - 2026)

Charles River Laboratories International has reported Revenue for 18 years, with the latest figure at $1.0 billion in Q2 2026.

• On a quarterly basis, Revenue fell 2.72% year-over-year to $1.0 billion in Q2 2026; TTM through Jun 2026 was $4.0 billion, a 0.74% decrease from a year earlier, with the FY2025 full-year figure at $4.0 billion, down 0.85% from the prior year.
• Revenue was $1.0 billion for Q2 2026 at Charles River Laboratories International, up from $995.8 million in the prior quarter.
• The five-year high for Revenue was $1.1 billion in Q4 2022, with the low at $913.9 million in Q1 2022.
• Average Revenue over 5 years is $1.0 billion, with a median of $1.0 billion recorded in 2024.
• The sharpest annual moves came in 2022 and 2023: Revenue increased 21.52% in 2022, then fell 7.85% in 2023.
• Over 5 years, Revenue stood at $1.1 billion in 2022, then retreated by 7.85% to $1.0 billion in 2023, then declined by 1.08% to $1.0 billion in 2024, then declined by 0.83% to $994.2 million in 2025, then gained by 0.99% to $1.0 billion in 2026.
• The last three Revenue figures came in at $1.0 billion (Q2 2026), $995.8 million (Q1 2026), and $994.2 million (Q4 2025), per Business Quant data.